[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609886":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":41,"responsibleParty":55,"collaborators":26,"id":57,"slug":26,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":26,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":26,"enrollmentInfo":65,"targetDuration":26,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":26,"overallStatus":44,"whyStopped":26,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Telios Pharma, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"TL-925 Arm","ACTIVE_COMPARATOR","Subjects will be dosed in clinic.",[13],"Drug: TL-925",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo Arm","PLACEBO_COMPARATOR","Subjects wil be dosed in clinic.",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","TL-925","TL-925 is an eye drop.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.",[15],[32,37],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Yulia Khalina","CONTACT","908-656-2799","ykhalina@teliospharma.com",{"name":38,"role":34,"phone":39,"phoneExt":26,"email":40},"John Mei","650-542-0136","jmei@teliospharma.com",[42],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":26},"Advancing Vision Research","RECRUITING","Smyrna","Tennessee","37167","United States",{"type":50,"coordinates":51},"Point",[52,53],-86.5186,35.98284,{"lat":53,"lon":52},{"type":56,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100609886",false,"NCT07220408","Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis","A Single Center, Randomized, Double-masked, Vehicle Controlled Phase 2 Study Evaluating the Safety and Efficacy of TL-925 Ophthalmic Emulsion 0.1% Compared to Vehicle for the Treatment of Seasonal Allergic Conjunctivitis in the Conjunctival Allergen Challenge (Ora-CAC®) Model","Inclusion Criteria:\n\n* Individuals aged 18 years or older\n* Female subjects of childbearing potential and their male partners must both use a highly effective contraception method during the study.\n* Documented history of ocular allergies and a positive skin test reaction to a seasonal (grass, ragweed, tree pollen) or perennial (cat dander, dog dander, dust mites, cockroach) allergen as confirmed by an allergic skin test conducted at Visit 1 or within the past 60 months.\n* Calculated best-corrected visual activity\n* Positive bilateral CAC reaction\n\nExclusion Criteria:\n\n* Any systemic or ocular disease currently producing ocular redness and\u002For ocular discomfort, or that may interfere with the conduct of the study.\n* Any ocular surgical intervention within the last 3 months OR refractive surgery within the last 6 months\n* Any ongoing ocular infection (bacterial, viral or fungal)","ALL","18 Years",{"count":66,"type":67},60,"ESTIMATED","INTERVENTIONAL",[70],"PHASE2","In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 60 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally.\n\nThe study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.",[73],"Allergic Conjunctivitis","2025-11-22",{"date":76,"type":77},"2025-11-25","ACTUAL",{"date":79,"type":77},"2025-10-23",{"date":81,"type":67},"2026-02",{"name":5,"class":6},1]